eligibility_summary
Eligibility: Age 1–70 with CD7‑positive relapsed/refractory T‑cell malignancy lacking options (post‑standard therapy), CD7 confirmed by flow cytometry or IHC, ECOG 0–2, life expectancy ≥60 days, able to consent (or guardian/assent). Key exclusions: intracranial hypertension/unconsciousness, acute HF/arrhythmia/respiratory failure, other cancers, DIC, renal dysfunction (>1.5× ULN), sepsis/uncontrolled infection, uncontrolled diabetes, severe psych disorder, MRI brain lesions, allergy, transplant recipient, pregnant/breastfeeding, active HBV/HCV/HIV/syphilis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Three CD7-directed CAR T-cell therapies—autologous, prior-HSCT donor–derived, and new donor–derived. Type: gene-modified cellular immunotherapy (CAR-T). Mechanism of action: patient or donor T cells are engineered to express a chimeric antigen receptor that binds CD7, CAR engagement activates T-cell effector functions, driving cytotoxic killing of CD7+ targets via TCR-like signaling and perforin/granzyme pathways with cytokine release. Targets: CD7 antigen on malignant T cells in relapsed/refractory T-ALL/T-LBL (bone marrow, CNS, extramedullary disease). Expected on-target effects include depletion of normal CD7+ T cells (and some NK cells), leading to T-cell aplasia.